|
|
|
|
|
07.10.25 - 08:03
|
Epsilogen Announces the Appointment of Cristina Oliva, MD, PhD as Chief Medical Officer (Business Wire)
|
|
|
Board-certified oncologist who brings over 20 years of senior clinical development experience across large pharmaceutical, biotechnology and Clinical Research OrganizationsLONDON--(BUSINESS WIRE)--Epsilogen, the world's leading pan-isotype antibody therapeutic company for the treatment of cancer, today announces the appointment of Cristina Oliva, MD, PhD, as Chief Medical Officer. Dr. Oliva is a Board-certified oncologist and brings global experience across all stages of oncology drug development.
Dr. Oliva joins Epsilogen from BerGenBio, where she served as Chief Medical Officer from 2022. Prior to this role, Dr. Oliva was Vice President, Oncology and Head of Oncology Centre of Excellence at IQVIA, where she led a cross-functional team of oncology subject matter experts and established and led the IQVIA Oncology Global Scientific Advisory Board. Dr. Oliva has also held senior positions, leading oncology development programs, at Nordic Nanovector, Takeda Pharmaceuticals, GSK and Eli Lilly.
Tim Wilson, CE...
|
|
|
|
|
02.10.25 - 02:03
|
Blue Matter stellt mit Eva Kersey einen neuen Partner ein und baut damit seine Kompetenzen in Europa weiter aus (Business Wire)
|
|
|
LONDON--(BUSINESS WIRE)--Blue Matter freut sich mitteilen zu können, Eva Kersey als Partner mit Sitz in London für das Unternehmen gewonnen zu haben. Eva ist dem Team von Blue Matter am 16. September offiziell beigetreten und bringt umfangreiche Erfahrungen in der strategischen Beratung von Kunden aus den Bereichen Pharmazie, Biotechnologie und Medizintechnik mit.
Eva ist seit 2007 für Kunden aus dem Bereich Life Sciences tätig. Sie startete ihre Beraterkarriere bei PHP (jetzt Teil von Accenture). Seitdem bekleidete sie Führungs- und Partnerpositionen bei IMS Consulting, IQVIA und ClearView Healthcare Partners. Über die Jahre konnte sie Beratungserfahrung entlang der gesamten Wertschöpfungskette sammeln, wobei ihr Schwerpunkt auf der Entwicklung funktionsübergreifender Strategien lag. Sie hat sich vor allem auf Therapie- und Franchise-Strategien, Portfoliooptimierung sowie Preis-, Zugangs- und Evidenzstrategien spezialisiert. Außerdem verfügt sie über umfassende Expertise in allen Aspekten der ...
|
|
|
01.10.25 - 15:06
|
Blue Matter Hires New Partner, Eva Kersey, Further Strengthening Capabilities in Europe (Business Wire)
|
|
|
LONDON--(BUSINESS WIRE)--Blue Matter is pleased to announce that Eva Kersey has joined the firm as a Partner based in London. Eva officially joined the Blue Matter team on September 16, bringing a broad base of strategic consulting experience across pharmaceutical, biotech, and medical technology clients.
Eva has been serving life science clients since 2007. She began her consulting career at PHP (now a part of Accenture). Since then, she has served in leadership and Partner-level positions at IMS Consulting, IQVIA, and ClearView Healthcare Partners. Over the years, her consulting experience has spanned the full value chain, focusing on cross-functional strategy development. She brings a particular specialization in therapy and franchise strategy, portfolio optimization, and pricing, access and evidence strategy. She also brings significant expertise in all aspects of commercial strategy development for clinical-stage, pre-launch assets.
“I'm extremely excited to join the Blue Matter team,” Eva said....
|
|
|
30.09.25 - 22:18
|
IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025 (Business Wire)
|
|
|
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its third-quarter 2025 financial results before the market opens on Tuesday, October 28, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.
To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive a confirmation email containing details on how to join the conference call, including the dial-in and a unique p...
|
|
|
|
|
|
|
|
|
|
|
|
|
02.09.25 - 15:03
|
IQVIA Announces CFO Transition in Early 2026 (Business Wire)
|
|
|
Ron Bruehlman to become Senior Advisor to CEO; Michael Fedock Named as New CFORESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences and healthcare industries, today announced a planned leadership transition in its finance organization. Michael Fedock, currently Senior Vice President of Financial Planning & Analysis, has been appointed Executive Vice President and Chief Financial Officer, effective February 28, 2026. He will succeed Ron Bruehlman, who will retire as CFO after a distinguished tenure. Mr. Bruehlman will continue to serve as Senior Advisor to Chief Executive Officer Ari Bousbib, ensuring continuity and a seamless transition.
“Ron has been a cornerstone of IQVIA's transformation and growth,” said Ari Bousbib. “His strategic leadership and financial stewardship have helped position IQVIA as a global leader. I am grateful for his...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
